Efficacy and safety of ruxolitinib in the treatment of myelofibrosis
- VernacularTitle:芦可替尼治疗骨髓纤维化的疗效与安全性
- Author:
Wanwan WANG
1
;
Jun YE
1
;
Hai CHENG
2
;
Wei YAO
1
;
Guiling LIU
1
Author Information
1. Dept. of Hematology，the Third People’s Hospital of Bengbu，Anhui Bengbu 233000，China
2. Dept. of Hematology，the Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221000，China
- Publication Type:Journal Article
- Keywords:
ruxolitinib;
myelofibrosis;
efficacy;
safety
- From:
China Pharmacy
2025;36(14):1781-1785
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the efficacy and safety of ruxolitinib in the treatment of myelofibrosis （MF）. METHODS A retrospective collection of data was conducted on 42 MF patients who were treated with ruxolitinib in a standardized manner for more than 6 months in the Third People’s Hospital of Bengbu from September 2018 to April 2024. The clinical symptom scores， spleen size reduction， and MF grading of the patients before and after treatment were analyzed. Additionally， the occurrence of adverse reactions with a causality assessment result of “definite”“probable” or “possible” was recorded. The patients’ survival status was followed up. RESULTS After 6 months of treatment， both clinical symptom scores and the total score were significantly decreased than before treatment （P＜0.05）. The length and thickness of the spleen were significantly shorter than before treatment （P＜0.05）. MF classification in 5 patients decreased by 1 level compared with baseline， 1 case was level 2 and dropped to level 0， 14 patients remained stable. The main adverse reactions were anemia （26 cases）， thrombocytopenia （14 cases）， infection （11 cases）， and gastrointestinal discomfort （9 cases）. Thirty-nine patients survived， with a survival rate of 92.86%. CONCLUSIONS Ruxolitinib can effectively improve the clinical symptoms of patients with MF， shrink the spleen， stabilize and even improve MF grading， and holds promise for bringing long-term survival benefits to MF patients. Adverse reactions are mainly anemia， thrombocytopenia， infection and gastrointestinal discomfort.
